If you've ever stood at a pharmacy counter wondering how a pill could possibly cost that much, you're not confused. You're paying attention.
The reason drug pricing feels so irrational is because the money doesn't move in a straight line. It moves through a maze, and at every stop, someone (cough PBM cough) has a hand in the pocket.
The Middleman That Became the System
Pharmacy benefit managers were designed to negotiate lower drug prices on behalf of insurers, employers, and health plans. A reasonable idea, in theory. In practice, they've become something far more complicated — and far more profitable.
PBMs sit at the center of the prescription drug supply chain. In that position, they collect rebates from manufacturers, charge fees to pharmacies, influence which drugs land on formularies, and in many cases, own the pharmacies themselves. They are simultaneously the negotiator, the distributor, and the beneficiary.
How the money is supposed to flow
The real version is messier — because the PBM isn't just passing money through. It's extracting economics at every leg of the journey.
Why List Prices Stay High
This is the part that rarely gets said plainly.
The rebate system — the mechanism that's supposed to lower costs — can actually reward high list prices. Negotiations are often structured as a percentage off the sticker price, which means a bigger list price produces a bigger-looking rebate. The apparent "discount" and the high starting point coexist by design.
So the performance goes like this: raise the list price, negotiate the rebate, call it savings, and leave the patient to sort out the out-of-pocket math.
Meanwhile, cost sharing is often calculated on the list price, not the net price after rebates. The patient pays based on the fiction, not the reality. Everyone in the chain is "managing costs." And yet somehow the person standing at the counter still can't afford their prescription.
Everyone is "managing costs." And yet the person at the counter still can't afford their prescription.
The Maze Got Walls
PBMs aren't small, neutral intermediaries anymore. They're embedded inside some of the largest corporate structures in healthcare — tied to insurers, pharmacies, and specialty networks under the same parent company. That vertical integration means more control over where patients go, which drugs get used, and where the margin lands.
When the same corporate family owns more of the path, the incentives don't get more aligned. They get more opaque. The savings may exist somewhere in the system. They just don't reliably show up where the patient is standing.
The word "integrated" gets used a lot in this space. So does "aligned." Neither word appears on the explanation of benefits.
Why This Is a Structural Problem, Not a PBM Problem
I think PBMs are one of the biggest reasons drug pricing feels so broken — but not because they're uniquely villainous. It's because they sit at the center of a system that was designed to be hard to follow, and they benefit directly from that opacity.
They can credibly claim to be lowering costs while the structure still supports high list prices, hidden take rates, and formulary decisions that have nothing to do with what's best for the patient. That is straight-up their business model.
Until the incentives change — until transparency is required, until rebates flow to patients instead of supply chain intermediaries, until the conflicts of interest get surfaced and addressed — the maze stays standing. And patients keep needing a decoder ring just to pick up a prescription.
I'm obsessed with this topic right now. More soon.
— Tess
